Stay updated with breaking news from Exeter Science. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Two doses from either the Oxford/AstraZeneca or the Pfizer vaccine are over 80 per cent effective in preventing infection from the B1.617.2 variant of COVID-19, first discovered in India, a new UK government study has reportedly found.
1354 People wearing protective face masks wait to receive their second dose of COVISHIELD, a coronavirus disease (COVID-19) vaccine manufactured by Serum Institute of India, outside a vaccination centre in Kolkata on May 12, 2021. Reuters file photo London, May 22 Two doses from either the Oxford/AstraZeneca or the Pfizer vaccine are over 80 per cent effective in preventing infection from the B1.617.2 variant of COVID-19, first discovered in India, a new UK government study has reportedly found. The Oxford/AstraZeneca two-dose vaccine is also being produced by the Serum Institute of India as...
The Oxford/AstraZeneca two-dose vaccine is also being produced by the Serum Institute of India as Covishield and being administered among the adult population in India to protect against the deadly virus
A new UK government study shows that two doses of either the AstraZeneca or Pfizer Covid vaccine provide more than 80 per cent protection against the variant first found in India.